

# Contents

## SECTION 1

## INTRODUCTION

- 1. History of Tuberculosis..... 3**  
*Arvind Kumar, SK Kabra*
- ◆ Ancient Times: Archeological Evidences and Historical Records 3
  - ◆ Middle Ages: The King's Evil and Anatomical Revolution 3
  - ◆ 18th–19th Centuries: Identification of Infectious Origin and *Mycobacterium tuberculosis* 4
  - ◆ Tuberculosis Therapy: Preantibiotic Era 5 ◆ Tuberculosis Therapy: Antibiotic Era 5
  - ◆ Tuberculosis Therapy: Postantibiotic Era 5 ◆ History of Tuberculosis Control in India 6
  - ◆ Sanatoria in India 6 ◆ Tuberculosis Association of India 7 ◆ Tuberculosis Control Program in Independent India 7 ◆ District Tuberculosis Program 7 ◆ National Tuberculosis Control Project 7
  - ◆ Crisis of Tuberculosis Control and Development of Revised National Tuberculosis Control Program 8
  - ◆ Pediatric Tuberculosis and National Tuberculosis Control Program 8

## SECTION 2

## EPIDEMIOLOGY

- 2. Epidemiology of Tuberculosis..... 13**  
*Stephen M Graham*
- ◆ Global Burden of Tuberculosis 13 ◆ Global Burden of Tuberculosis in Children and Adolescents 15
  - ◆ Risks for Infection and Disease 16 ◆ Tuberculosis in Children and Adolescents in Context of Public Health 17
  - ◆ Understanding Child Tuberculosis Epidemiology and National Tuberculosis Program Data 18
  - ◆ Age-related Pattern of Tuberculosis in Children 19
- 3. Epidemiology of Pediatric Tuberculosis in India ..... 23**  
*Tanu Singhal, SK Kabra*
- ◆ Burden of Tuberculosis Infection in Indian Children 23 ◆ Burden of Tuberculosis Disease in Children 25
  - ◆ Types of Tuberculous Disease in Children 26 ◆ Outcomes of Tuberculosis in Indian Children 27
  - ◆ Drug-resistant Tuberculosis 27

## SECTION 3

## MICROBIOLOGY AND IMMUNOPATHOGENESIS

- 4. *Mycobacterium tuberculosis*..... 33**  
*Sarman Singh, Amit Singh, Jitendra Singh, K Gopinath, Ashok Rattan*
- ◆ Taxonomy 33 ◆ Description of the Genus 34 ◆ Diagnosis 49
- 5. Nontuberculous *Mycobacteria* ..... 52**  
*Sarman Singh, Amit Singh*
- ◆ Taxonomy 52 ◆ Classification of Nontuberculous *Mycobacteria* on the Basis of Pigment Production 52
  - ◆ Geographical Distribution of Nontuberculous *Mycobacteria* 53 ◆ Clinical Manifestations 54
  - ◆ Respiratory Disease 54 ◆ Diagnostic Criteria of Nontuberculous Mycobacterial Lung Disease 56
  - ◆ Lymphadenitis 56 ◆ Cutaneous and Soft-tissue Infections 58 ◆ Bone and Joint Infections 58
  - ◆ Disseminated Disease 58 ◆ Role of Ethnicity and Genetic Susceptibility to Nontuberculous *Mycobacteria* Infections 59 ◆ Association of Nontuberculous *Mycobacteria* with Other Diseases 59
  - ◆ Beneficial Effects of Nontuberculous *Mycobacteria* Infection 60
  - ◆ Laboratory Facilities for Establishing the Diagnosis 60

**6. Immunology of Tuberculosis: Basic Aspects..... 65***Harleen MS Grewal, SK Kabra*

- ♦ Virulence Factors of *Mycobacterium tuberculosis* 65 ♦ Immune Cells of the Body 67
- ♦ Cell Death 72 ♦ TB Pathogenesis 72

**7. Clinicoimmunological Profile of Tuberculosis ..... 76***Samriti Gupta, SK Kabra*

- ♦ Natural Course after Exposure to *Mycobacterium tuberculosis* 76
- ♦ Role of Innate and Adaptive Immunity in Pathogenesis of Tuberculosis 76
- ♦ Distinctive Immunological Response in Children 78 ♦ Clinical Phenotype and Immunity 79
- ♦ Paradoxical Reactions/Immune Reconstitution Inflammatory Syndrome 80

**SECTION 4****CLINICAL SPECTRUM****8. Pulmonary Tuberculosis ..... 85***Nitin Dhochak, SK Kabra*

- ♦ Transmission 85 ♦ Pathophysiology 85 ♦ Risk of Infection to Disease in Infants and Young Children 86
- ♦ Natural History of Tubercular Infections 86 ♦ Principles of Disease 86 ♦ Clinical Features 90
- ♦ Diagnosis 91 ♦ Treatment 95

**9. Peripheral Tuberculous Lymphadenitis ..... 99***Abhinav Rajkumar, Gayana PS Gunaratna, Ben J Marais*

- ♦ Epidemiology 99 ♦ Pathogenesis 100 ♦ Clinical Findings 101 ♦ Diagnosis 102
- ♦ Tuberculin Skin Test and Interferon- $\gamma$  Release Assay 103 ♦ Management 103
- ♦ Tuberculous Lymphadenitis—Indian Experience 104

**10. Abdominal Tuberculosis ..... 106***Rishi Bolia, Anshu Srivastava*

- ♦ Pathogenesis 106 ♦ Clinical Features 106 ♦ Disease Distribution 107 ♦ Diagnosis 109
- ♦ Differential Diagnosis 114 ♦ Complications 114 ♦ Treatment 114 ♦ Outcome 116

**11. Neurotuberculosis ..... 119***Prashant Jauhari, Ankit Meena, Gautam Kamila, Prabhjot Kaur, Suvasini Sharma, Sheffali Gulati***11.1. Pathogenesis of Central Nervous System Tuberculosis ..... 119***Prashant Jauhari, Ankit Meena, Gautam Kamila*

- ♦ Dissemination to Central Nervous System 119 ♦ Interaction with the Host within the Brain 120
- ♦ Genetic Factors 120 ♦ Role of Bacillus Calmette–Guérin Vaccine in Preventing Tuberculous Meningitis 121
- ♦ Pathological Attributes of Clinical Syndromes in Tuberculous Meningitis 121

**11.2. Clinical Manifestations, Diagnosis, and Management ..... 129***Prabhjot Kaur, Suvasini Sharma*

- ♦ Epidemiology 129 ♦ Pathogenesis 129 ♦ Clinical Features 129 ♦ Complications of Tuberculous Meningitis 130 ♦ Diagnosis of Tubercular Meningitis 131 ♦ Serological Testing in Cerebrospinal Fluid 133
- ♦ Evidence of Extranural Tuberculosis 134 ♦ Management of Tubercular Meningitis 135
- ♦ New and Upcoming Treatment 135 ♦ Medical Management of Cerebral Edema 138 ♦ Paradoxical Response to Antitubercular Treatment 138 ♦ Surgical Management of Hydrocephalus 138 ♦ Prognosis 139
- ♦ Mortality and Sequelae 139 ♦ Special Scenarios 139 ♦ Spinal Tuberculosis in Children 141

**11.3. Case Studies ..... 148***Sheffali Gulati, Gautam Kamila*

- ♦ Profile of Tuberculous Meningitis in Children Modified by Bacillus Calmette–Guérin 148
- ♦ Profile of Neurotuberculosis: AIIMS Experience 153

- 12. Osteoarticular Tuberculosis ..... 165**  
*Venkatesan Sampath Kumar, Love Kapoor, Shah Alam Khan*  
 ♦ Joint Involvement 166 ♦ Clinical Features 166 ♦ Investigations 166 ♦ Differential Diagnosis 168  
 ♦ Management 169 ♦ Tuberculosis of the Hip Joint 170 ♦ Tuberculosis of the Knee Joint 173  
 ♦ Tuberculosis of the Ankle and Elbow 173 ♦ Tuberculosis of the Short Long Bones 174  
 ♦ Tuberculosis of the Spine (Pott's Spine) 174
- 13. Genitourinary Tuberculosis..... 181**  
*Arvind Bagga*  
 ♦ Pathogenesis 181 ♦ Clinical Features 182 ♦ Diagnosis 182 ♦ Therapy 183  
 ♦ Dose Modification in Renal Failure 183 ♦ Surgical Treatment 183
- 14. Tuberculosis and HIV Coinfection..... 185**  
*Tanu Singhal*  
 ♦ Epidemiology 185 ♦ Pathogenesis 186 ♦ Clinical Features 187 ♦ Diagnosis 187  
 ♦ Differential Diagnosis for Pulmonary Tuberculosis 190 ♦ Treatment 190  
 ♦ Immune Reconstitution Inflammatory Syndrome 192 ♦ HIV Exposed Uninfected Children 192  
 ♦ Prognosis 192 ♦ Multidrug-resistant Tuberculosis and HIV 192  
 ♦ Prevention of Tuberculosis in HIV-infected Children 193
- 15. Tuberculosis and Childhood Malignancy..... 199**  
*Rachna Seth, Debasish Sahoo*  
 ♦ Immunology of Tubercular Infection 200 ♦ Immunopathology of Tuberculosis 200  
 ♦ Prevalence of Latent Tuberculosis Infection and Active Tuberculosis in Pediatric Cancer 200  
 ♦ Clinical Features 201 ♦ Risk Factors 202 ♦ Diagnosis of Latent Tuberculosis Infection 202  
 ♦ Diagnosis of Active Tubercular Disease 202 ♦ Misdiagnosis: Malignancy or Tuberculosis 203  
 ♦ Chemotherapy and Reactivation of Tuberculosis 204 ♦ Treatment Response to Antitubercular Therapy  
 in Pediatric Cancer Patients 205 ♦ Hematopoietic Stem Cell Transplantation and Tuberculosis 206
- 16. Unusual Manifestations of Tuberculosis ..... 209**  
*Prawin Kumar, Jagdish Prasad Goyal*  
 ♦ Tuberculosis of Eye 209 ♦ Tuberculosis of Heart 211 ♦ Hematological Complications 212  
 ♦ Esophageal Tuberculosis 213 ♦ Tuberculous Otitis Media and Mastoiditis 214  
 ♦ Cement Kidney: Renal Tuberculosis 214 ♦ Tuberculosis of Oral Cavity 214  
 ♦ Tuberculosis of the Breast in Adolescent Girls 215 ♦ Pituitary Stalk Tuberculosis 215  
 ♦ Multifocal Skeletal Tuberculosis 215 ♦ Primary Epiphyseal Osteomyelitis 216
- 17. Cutaneous Tuberculosis ..... 219**  
*Saurabh Bhatia, Neena Khanna*  
 ♦ Epidemiology 219 ♦ Etiology 219 ♦ Pathogenesis 219 ♦ Classification 219  
 ♦ Clinical Features 220 ♦ Unusual Patterns of Tuberculosis 223  
 ♦ Diagnosis 223 ♦ Treatment of Cutaneous Tuberculosis 224
- 18. Adolescent Tuberculosis: Prelude to Future Infertility ..... 227**  
*JB Sharma, Sangeeta Sharma, Sona Dharmendra*  
 ♦ Epidemiology and Pathogenesis of Adolescent Female Genital Tuberculosis 227  
 ♦ Tuberculosis of Fallopian Tubes 227 ♦ Endometrial Tuberculosis 228 ♦ Ovarian Tuberculosis 228  
 ♦ Peritoneal Tuberculosis 228 ♦ Tuberculosis of Cervix, Vagina, and Vulva 229  
 ♦ Adolescent Tuberculosis and Future Infertility 229  
 ♦ Clinical Presentation of Female Genital Tuberculosis in Adolescent Girl 229  
 ♦ Differential Diagnosis 229 ♦ Diagnosis 229 ♦ Treatment 233  
 ♦ Future of Tuberculosis Research 235

- 19. Endocrine Manifestations of Tuberculosis.....237**  
*Rajni Sharma, Devasenathipathy Kandasamy, Anju Seth*
- ♦ Systemic Manifestations 237 ♦ Endocrine Gland Involvement 238
  - ♦ Hypothalamic–pituitary Axis Involvement in Tuberculosis 239 ♦ Pituitary Gland Involvement 239
  - ♦ Hyponatremia, Cerebral Salt Wasting, and Syndrome of Inappropriate Antidiuretic Hormone 240
  - ♦ Thyroid Tuberculosis 240 ♦ Pancreatic Tuberculosis 240 ♦ Genital Tuberculosis 241
  - ♦ Manifestations due to Therapy 241
- 20. Congenital Tuberculosis .....243**  
*Manish Swami, Tanushree Sahoo, Krishna Mohan Gulla*
- ♦ Pathophysiology 243 ♦ Clinical Features of the Mother 244 ♦ Clinical Features of the Neonate 244
  - ♦ Diagnostic Criteria for Congenital Tuberculosis 245 ♦ Investigations 246
  - ♦ Late Neonatal Respiratory Distress: A Presentation of Congenital Tuberculosis 247 ♦ Treatment 247

## SECTION 5

## DIAGNOSIS

- 21. Tuberculin Test .....253**  
*Vijaya Kumar, Rakesh Lodha*
- ♦ What is Tuberculin Skin Test? 253 ♦ Basis of Tuberculin Test 253
  - ♦ Are there any Risks from Having the Purified Protein Derivative Skin Test? 253 ♦ History 254
  - ♦ Tuberculins 254 ♦ Composition 255 ♦ Immune Basis of Tuberculin Reactivity 255
  - ♦ Tuberculosis and Immune System 256 ♦ Administration of Tuberculin Test 257
  - ♦ Infection with Nontuberculous Mycobacteria 258 ♦ Bacillus Calmette–Guérin Vaccination 258
  - ♦ Variables Affecting Interpretation 259
- 22. Newer Tuberculin—CTB: Profile in Developing Countries .....268**  
*Poornaganga Devi, C Padmapriyadarsini*
- ♦ Purified Protein Derivative 268 ♦ Tuberculin Skin Test 268 ♦ ESAT–CFP-10 Assay 269
  - ♦ Immunodiagnostic Test 269 ♦ C-TB 269
- 23. Airway Specimen Collection .....275**  
*Isha Saini*
- ♦ Specimen-collection Methods for Pulmonary Tuberculosis Disease 276
- 24. Imaging of Tuberculosis in Children.....279**  
*Manisha Jana, Priyanka Naranje, Ashu Seith Bhalla, Atin Kumar, Ankur Goyal, Devasenathipathy Kandasamy*
- 24.1. Imaging in Pediatric Thoracic Tuberculosis .....279**  
*Manisha Jana, Priyanka Naranje, Ashu Seith Bhalla*
- ♦ Imaging Modalities 279 ♦ Pulmonary Tuberculosis 282 ♦ Response Assessment 288
- 24.2. Imaging of Extrathoracic Tuberculosis in Children .....290**  
*Atin Kumar, Ankur Goyal, Devasenathipathy Kandasamy*
- ♦ Intracranial Tuberculosis 290 ♦ Urogenital Tuberculosis 293 ♦ Abdominal Tuberculosis 296
  - ♦ Musculoskeletal Tuberculosis 299
- 25. Pathologic Spectrum .....305**  
*Sandeep R Mathur, Aanchal Kakkar*
- ♦ Pathologic Spectrum of Tuberculosis in Children 305 ♦ Spectrum of Morphologic Changes 310
- 26. Diagnostic Approach to Tuberculosis in Children .....317**  
*Annaleise R Howard-Jones, Ameneh Khatami, Ben J Marais*
- ♦ Screening Child Contacts for Tuberculosis Infection 317 ♦ Diagnosis of Tuberculosis Disease 319
  - ♦ Specimen Collection Methods in Children 323 ♦ Human Immunodeficiency Virus Infection 323

## SECTION 6

## MANAGEMENT

- 27. Principles of Therapy of Tuberculosis.....331**  
*Jagat Jeevan Ghimire, SK Kabra*  
 ♦ Aims of Antitubercular Therapy 331 ♦ Principles of Antitubercular Therapy 331  
 ♦ Concept of Core Drug and Companion Drug and their Position in Regimen Formation 333  
 ♦ Development of the Concept of Two-phase Chemotherapy and Properly Applied Short-course Chemotherapy 334  
 ♦ HIV–Tuberculosis Coinfection 335 ♦ Disease Principles Specific to Pediatrics 335
- 28. Antituberculosis Drugs: First-line Agents.....337**  
*Aakanksha Anand, Anshula Tayal*  
 ♦ Classification of Drugs 337 ♦ Isoniazid 339 ♦ Rifampicin (Rifampin) 342 ♦ Pyrazinamide 344  
 ♦ Ethambutol 345 ♦ Streptomycin 346 ♦ Fixed-dose Drug Combination for Treatment of Tuberculosis 348
- 29. Antituberculosis Drugs: Second-line and Newer Agents.....354**  
*Aakanksha Anand, Anshula Tayal, SK Kabra*  
 ♦ Currently Recommended Drug-resistant Tuberculosis Regimens 355 ♦ Second-line Agents 355  
 ♦ Miscellaneous Agents 368 ♦ Treatment of Tuberculosis and Human Immunodeficiency Virus Together 371  
 ♦ The New Investigational Drugs 371 ♦ Immunomodulation 372 ♦ Nanomedicine Formulation 372  
 ♦ Tuberculosis-preventive Therapy for Contacts of DR-TB 373
- 30. Antituberculosis Drugs: Pharmacokinetics .....378**  
*Saibal Das, Aparna Mukherjee*  
 ♦ Pharmacological Principles of Antitubercular Therapy 378 ♦ Principles of Dosing of Antituberculous  
 Drugs in Children 381 ♦ Detailed Considerations of Pharmacokinetics of Each Antitubercular Drug in Children:  
 a Review of the Existing Evidence 384 ♦ Fixed-dose Combination 393
- 31. Pharmacogenetics of Tuberculosis.....399**  
*Manju Ghosh, Soumalya Chakraborty, Madhulika Kabra*  
 ♦ What is Pharmacogenetics? 399 ♦ Pharmacogenomics 399 ♦ Pharmacogenetics/Genomics of  
 Tuberculosis 400 ♦ Isoniazid 400 ♦ Hepatotoxicity 401 ♦ Rifampicin 401 ♦ Pyrazinamide 402  
 ♦ Ethambutol 402 ♦ Molecular Diagnosis of Multidrug-resistant Tuberculosis 402
- 32. Management of Tuberculosis.....405**  
*Anshula Tayal, SK Kabra*  
 ♦ Commonly Used Drugs 405 ♦ First-line Antitubercular Drug Regimens 405  
 ♦ Corticosteroids in Tuberculosis 406 ♦ Pyridoxine Supplementation 407  
 ♦ Monitoring of Treatment 407 ♦ Monitoring for Side Effects 408
- 33. Drug-resistant Tuberculosis in Children .....412**  
*H Simon Schaaf*  
 ♦ Historical Perspective 412 ♦ How Children Get Drug-resistant Tuberculosis? 414 ♦ Current Epidemiology  
 of Drug-resistant Tuberculosis 415 ♦ Human Immunodeficiency Virus and Drug-resistant Tuberculosis 415  
 ♦ Diagnosing Drug-resistant Tuberculosis in Children 416 ♦ Management of Drug-resistant Tuberculosis 416  
 ♦ Outcome of Multidrug-resistant Tuberculosis in Children 423 ♦ Management of Child Contacts of Infectious  
 Drug-resistant Tuberculosis Cases 423 ♦ Infection and Prevention Control Measures 423
- 34. Organization of Pediatric Tuberculosis Clinic.....427**  
*Rakesh Lodha, Tanu Singhal, SK Kabra*  
 ♦ Starting Tuberculosis Clinic for Children 427 ♦ Organization of Services 429  
 ♦ Annexure 1 431 ♦ Annexure 2 432 ♦ Annexure 3 435 ♦ Annexure 4 435  
 ♦ Annexure 5: Interruption of Antituberculosis Treatment 436 ♦ Annexure 6 437  
 ♦ Annexure 7 438 ♦ Annexure 8 438

<b>35. Bacillus Calmette–Guérin Vaccination .....</b>	<b>439</b>
<i>Swati Dublish, SK Kabra</i>	
♦ Mechanism of Protection of Tuberculosis Disease by Bacillus Calmette–Guérin	439
♦ Indications for Bacillus Calmette–Guérin Vaccination	439
♦ Storage	440
♦ Reconstitution	440
♦ Dosage	440
♦ Administration	440
♦ Natural History of Bacillus Calmette–Guérin Vaccination	440
♦ Contraindications to Bacillus Calmette–Guérin Vaccination	440
♦ Should the Children be Revaccinated?	441
♦ Adverse Reactions	441
♦ Bacillus Calmette–Guérin Vaccination and Human Immunodeficiency Virus Infection	441
♦ Characteristics of Bacillus Calmette–Guérin Disease	442
♦ Efficacy of Bacillus Calmette–Guérin Vaccination	442
♦ Other Antituberculosis Vaccines	442
<b>36. Latent Tuberculosis.....</b>	<b>445</b>
<i>Sagar Tungal, SK Kabra</i>	
♦ Burden of the Disease	445
♦ Natural Course of Tuberculosis Infection	445
♦ Rationale of TPT	446
♦ Identification of Populations for Evaluation	446
♦ Screening of High-risk Populations	446
♦ Contraindications for Starting Tuberculosis-preventive Therapy in Children	446
♦ Diagnosis	446
♦ Tuberculosis-preventive Treatment	450
♦ Monitoring	453
♦ Management of Missed Treatment	453
♦ Adverse Events	453
<b>37. Symptom-based Screening of Child Tuberculosis Contacts: Improved Feasibility in Resource Limited Settings.....</b>	<b>458</b>
<i>Bryan Vonasek, Rina Triasih, Ben J Marais</i>	
♦ Symptom-based Child Contacts Screening	458
♦ Tuberculosis-preventive Treatment	461
♦ Tuberculin Skin Testing	462
♦ Symptom-based Screening in Children Living with Human Immunodeficiency Virus	462
<b>38. Tuberculosis Elimination Program in Children: Progress and Way Forward.....</b>	<b>465</b>
<i>Sangeeta Sharma</i>	
♦ Protocol-based Approach	465
♦ Treatment and Drug Availability	466
♦ Adherence to Treatment	467
♦ Notification	467
♦ Tuberculosis- and HIV-control Strategies	467
♦ Contact Tracing and Chemoprophylaxis	468
♦ Special Needs of Children	468
♦ Newer Initiatives	468
<b>39. Frequently Asked Questions about Tuberculosis.....</b>	<b>470</b>
<i>Sheetal Agarwal, SK Kabra</i>	
♦ General Information about Tuberculosis in Children	470
♦ Misconceptions about Tuberculosis in Children	470
♦ How is Tuberculosis in Children Different from that in Adults?	471
♦ Transmission of Tuberculosis to Children	471
♦ Pathogenesis	471
♦ How is Tuberculosis in Children Diagnosed?	471
♦ How Should the Drug-induced Liver Injury be Managed?	474
♦ Treatment of Tuberculosis Patients	475
♦ Drugs used in the Management of Tuberculosis with Human Immunodeficiency Virus Coinfection	476
♦ Tuberculosis Treatment Regimens: Questions and Answers	476
♦ Uses of Antituberculosis Drugs in Special Situations	476
♦ Role of Steroid Treatment	476
♦ Side Effects of Antituberculosis Drugs	477
♦ Where to Manage Drug Reactions?	477
♦ Reintroduction of Antituberculosis Drugs Following Drug Reaction	477
<b>Index.....</b>	<b>479</b>